- Also known as
- TB500 · TB 500 · thymosin beta-4 · thymosin β4 · Tβ4
- Class
- Thymosin beta-4 related peptide (actin-binding)
- Form
- Lyophilised powder in 10 mg vials
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
What is TB-500?
The literature describes TB-500 as thymosin beta-4 related peptide (actin-binding). Published work on it is in human and mouse. The name covers the same material written several ways in the literature, including TB500, TB 500 and thymosin beta-4. Its sequence is recorded as Sold under the TB-500 name. The research literature studies thymosin beta-4, a 43-amino-acid peptide.. People have received it in 3 studies, none of them controlled, which means those results cannot separate the compound from everything else that changed. Supplied as lyophilised powder in 10 mg vials, held in Canadian stock, for laboratory research. It is not authorized as a medicine and is not for use in any living subject.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Drum CL et al.2017 · J Am Heart Assoc · PMID 28611096 | Human, observational biomarker study (HFpEF n=219, HFrEF n=219, controls n=219); circulating TB4 measured, none given | None given (the body's own plasma TB4 was measured) | Not stated in the abstract | Plasma TB4 was higher in HFpEF than in controls (1401 vs 985 ng/mL, P<0.001), an effect seen in women only. In women with heart failure, elevated TB4 carried a higher hazard ratio for all-cause death (1.668, P=0.036). |
| Sun YS et al.2025 · World J Gastroenterol · PMID 41278163 | Human colonic mucus (IBS patients); mouse and rat (Tβ4-deficient) models | Not stated in the abstract | Not stated in the abstract | Tβ4 treatment of mice reduced tight junction proteins in the gut lining, and Tβ4 released from mast cells under stress disrupted the intestinal epithelial barrier. Tβ4-deficient rats were resistant to stress-induced barrier disturbance. |
| Jin Z et al.2025 · Cell Signal · PMID 40912522 | Human breast cancer tissue and cell lines; mouse (in vivo) | Not stated in the abstract | Not stated in the abstract | Tβ4 was upregulated in breast cancer tissue, and high expression correlated with poor clinical outcomes. Tβ4 promoted cancer cell proliferation, migration and angiogenesis by regulating SLC7A11 and inhibiting ferroptosis. |
| Maar K et al.2025 · Int J Mol Sci · PMID 40362372 | Mouse, permanent coronary ligation (heart attack) model; human cardiac cells | Systemic TB4 injection; amount not stated in the abstract | Not stated in the abstract | TB4 raised miR139-5p expression and modulated ROCK1 protein levels in mouse hearts and human cardiac cells, and may reverse or inhibit fibroblast-to-myofibroblast transformation. |
| Li Y et al.2025 · J Allergy Clin Immunol · PMID 39978686 | Mouse, house dust mite allergic asthma model (BDCA2-DTR mice); cell experiments | Tβ4 supplementation; amount not stated in the abstract | Not stated in the abstract | Tβ4 supplementation reversed the worsened asthma phenotype in mice depleted of plasmacytoid dendritic cells. Tβ4 inhibited IL-4/IL-13-induced JAK1/STAT6 signalling and CCL2 expression in macrophages. Serum Tβ4 was lower in mice and humans with ongoing allergic asthma. |
| Li H et al.2018 · J Gene Med · PMID 29972714 | Mouse, CCl4-induced liver fibrosis model (gene delivery, not peptide); liver cells in vitro | Intraperitoneal adeno-associated virus encoding Tβ4 (AAV-Tβ4); amount not stated in the abstract | Not stated in the abstract | AAV-Tβ4 pre-treatment significantly reduced liver injury, collagen deposition, stellate cell activation and pro-fibrotic cytokines, partly by down-regulating TGF-β receptor II. |
| Bako P et al.2023 · Int Immunopharmacol · PMID 38706788 | Mouse tympanic membrane (eardrum) explants, ex vivo and on collagen gels | Not stated in the abstract | Not stated in the abstract | TB4 affected the migration and proliferation of epidermal and epithelial cells of the tympanic membrane in vitro, most likely acting on local epidermal progenitor cells. |
What these studies don't show: The human work here is uncontrolled: pilot studies, case reports and retrospective reviews. No control arm means no way to attribute the change to the compound. These are short studies in few people, which says nothing about sustained use. Testing establishes identity and purity; it is not evidence of an effect.
Every study links to its PubMed record. See all TB-500 studies in the research library →
TB-500 price in Canada: 10mg vial
Buy TB-500 in Canada in a 10mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $62.00 | $6.20/mg |
Starter kit
Is TB-500 available in Canada?
No product containing TB-500 holds a Drug Identification Number in Canada. No regulatory assessment of its safety, efficacy or quality has been carried out in Canada. Borealis Peptides holds it for in-vitro research; it is not supplied for use in any living subject. How Health Canada treats research peptides →
Side effects reported in studies
Absence of a reported effect in a small study is not evidence of safety. Each statement is tied to the study that reported it. None of the cited abstracts states a tolerability finding for TB-500.
TB-500 FAQ
What is TB-500?
Chemically, TB-500 is classed as thymosin beta-4 related peptide (actin-binding). The published work on it is in human and mouse. Borealis Peptides supplies it as lyophilised powder in 10 mg vials for in-vitro laboratory research. It is not a drug, and it is not supplied for use in a person or an animal. Below, every cited paper is shown with the system it used and what it found.
Where can I buy TB-500 in Canada?
Direct from Borealis Peptides, held in Canadian stock so nothing crosses a border on its way to you. Stocked in 10 mg vials. Purity is confirmed by HPLC batch by batch, and we supply for laboratory research only. HPLC runs on each batch, and the certificate you receive refers to the batch you were sent.
Is TB-500 legal in Canada?
No product containing TB-500 holds a Drug Identification Number in Canada. No regulatory assessment of its safety, efficacy or quality has been carried out in Canada. Borealis Peptides holds it for in-vitro research; it is not supplied for use in any living subject. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission.
How much TB-500 should I use?
Borealis Peptides gives no dosing, protocols or reconstitution volumes, and will not provide them on request. In laboratory work the amount follows from the study design, which a supplier cannot sensibly set. The figures on this page are what specific published studies used in their own models: a record of what was done, not a recommendation.
What human evidence is there for TB-500?
There is human work, but none of it is controlled. 3 studies involved people, as pilots, case reports or retrospective reviews. Without a control group these cannot show that the compound caused what was observed, and the page says so beside the table.
How is TB-500 stored?
Storage for the sealed vial is −20 °C, away from light and moisture. Solutions are held at 2–8 °C. It travels at room temperature as a dry powder and goes cold on arrival. What degrades a lyophilised peptide is light and temperature cycling rather than transit time.
How is the purity of TB-500 confirmed?
Every batch is tested by HPLC before it is sold, and the certificate refers to the batch in your vial rather than to the product in general. Keeping that batch number with your records is what makes an observation reproducible later. Certificates are available on request.
How does TB-500 compare with BPC-157 and Wolverine blend (BPC-157 + TB-500)?
Each has its own published record, and comparing them is a matter of reading both. BPC-157 and Wolverine blend (BPC-157 + TB-500) have 7 cited studies and 8 cited studies on their page against 7 here. Reading both tables, with the models each used, is the comparison worth making.
Why is TB-500 named in a Health Canada advisory?
Because it was among the peptides seized from sellers offering unauthorized injectable products online. The advisory concerns material sold for people to inject without authorization. Borealis Peptides supplies research material for laboratory use and sells nothing for injection or for any use in a person, which is the line that advisory draws.







